These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model. Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS Front Immunol; 2021; 12():737076. PubMed ID: 34659228 [TBL] [Abstract][Full Text] [Related]
25. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Webb JR; Milne K; Nelson BH Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117 [TBL] [Abstract][Full Text] [Related]
26. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma. Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025 [TBL] [Abstract][Full Text] [Related]
27. Distribution, phenotype, functional and clinical relevance of CD8 Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045 [TBL] [Abstract][Full Text] [Related]
28. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842 [TBL] [Abstract][Full Text] [Related]
29. Significance of CD103 Natsuki S; Tanaka H; Nishiyama M; Deguchi S; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K BMC Cancer; 2023 Oct; 23(1):1011. PubMed ID: 37864146 [TBL] [Abstract][Full Text] [Related]
30. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886 [TBL] [Abstract][Full Text] [Related]
31. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8 Gauthier L; Corgnac S; Boutet M; Gros G; Validire P; Bismuth G; Mami-Chouaib F Cancer Res; 2017 Dec; 77(24):7072-7082. PubMed ID: 29021139 [TBL] [Abstract][Full Text] [Related]
32. Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. Chang YH; Heo YJ; Cho J; Song SY; Lee J; Kim KM Sci Rep; 2018 Sep; 8(1):13887. PubMed ID: 30224753 [TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978 [TBL] [Abstract][Full Text] [Related]
34. CD155T/TIGIT Signaling Regulates CD8 He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004 [TBL] [Abstract][Full Text] [Related]
35. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937 [TBL] [Abstract][Full Text] [Related]
36. Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer. Yan R; Yang X; Wang X; Wang B; Zhao Y; Huang W; Zhao W; Jia L Med Sci Monit; 2019 Sep; 25():6916-6921. PubMed ID: 31519868 [TBL] [Abstract][Full Text] [Related]
37. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G Front Immunol; 2021; 12():637146. PubMed ID: 34025646 [TBL] [Abstract][Full Text] [Related]